Cargando…

Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience

BACKGROUND: Sofosbuvir (SOF)-based regimens achieve excellent efficacy and safety in the treatment of chronic hepatitis C (CHC) with various genotypes. There are few real-world instances of the use of SOF-based regimens to treat genotype 2 CHC. This study determines the effectiveness and safety of S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Wei-Lun, Wang, Chih-Feng, Cheng, Jin-Shiung, Chen, Wen-Chi, Bair, Ming-Jong, Lo, Ching-Chu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953822/ https://www.ncbi.nlm.nih.gov/pubmed/31923251 http://dx.doi.org/10.1371/journal.pone.0227424

Ejemplares similares

Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
por: Cheng, Pin-Nan, et al.
Publicado: (2021)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
por: Han, Qunying, et al.
Publicado: (2019)

Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
por: Liou, Bo-Huang, et al.
Publicado: (2021)

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
por: Chang, Te-Sheng, et al.
Publicado: (2023)

Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
por: Liu, Chen-Hua, et al.
Publicado: (2018)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
por: Huang, Yu-Ting, et al.
Publicado: (2021)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Sofosbuvir induces gene expression for promoting cell proliferation and migration of hepatocellular carcinoma cells
por: Tsai, Wei-Lun, et al.
Publicado: (2022)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

Real World Experience of Sofosbuvir/Ledipasvir Therapy in HIV Patients Co-infected with HCV: A Retrospective Study
por: Al Obaidi, Mohanad, et al.
Publicado: (2017)

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam
por: Nguyen, Dung Thanh, et al.
Publicado: (2020)

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
por: Do, Albert, et al.
Publicado: (2015)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand
por: Sirinawasatien, Apichet, et al.
Publicado: (2020)

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016)

Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients
por: Smirne, Carlo, et al.
Publicado: (2022)

Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts
por: Mangia, Alessandra, et al.
Publicado: (2020)

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
por: Ji, Fanpu, et al.
Publicado: (2017)

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan
por: Huang, Ying-Chou, et al.
Publicado: (2021)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
por: McQuaid, Thomas, et al.
Publicado: (2015)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
por: Lee, Soon Kyu, et al.
Publicado: (2022)

Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
por: Obed, Aiman, et al.
Publicado: (2016)

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients
por: Ajlan, A., et al.
Publicado: (2016)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
por: Orr, Cody, et al.
Publicado: (2020)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)

Treatment of HCV NS3/4a Protease Inhibitor Experienced Patients with Sofosbuvir Containing Regimens in an Outpatient Clinic
por: Gilroy, Shelley, et al.
Publicado: (2017)

Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
por: Mazzitelli, Maria, et al.
Publicado: (2018)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
por: Huhn, Gregory D., et al.
Publicado: (2020)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience
por: Butt, Nazish, et al.
Publicado: (2019)

The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
por: Tsai, Tzu‐Cheng, et al.
Publicado: (2019)

Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study
por: Tao, Ya-Chao, et al.
Publicado: (2018)

Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
por: Banga, Jaspreet, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nrn4nnfi0o50oa594l6fd33f00